Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$589.88 USD

589.88
515,500

+4.14 (0.71%)

Updated Jul 24, 2024 03:55 PM ET

After-Market: $590.28 +0.40 (0.07%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PerkinElmer's (PKI) Q4 Earnings Top, Revenues Decline Y/Y

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Ideas feature highlights: McKesson, Jabil and Halliburton

by Zacks Equity Research

McKesson, Jabil and Halliburton are part of the Zacks Investment Ideas article.

Benjamin Rains headshot

3 Highly-Ranked Stocks that Beat the Market in 2022 to Buy Now

by Benjamin Rains

Digging into three highly-ranked stocks that outperformed the market in 2022 amid the turmoil and are primed to keep running higher in 2023 even if Wall Street is forced to take its foot off the growth pedal.

Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase

by Zacks Equity Research

Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.

Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

by Zacks Equity Research

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

by Zacks Equity Research

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.

QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.

Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.

Should Value Investors Buy AmerisourceBergen (ABC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why McKesson (MCK) is Poised for a Turnaround After Losing -6.24% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

by Zacks Equity Research

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.

Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical

by Zacks Equity Research

McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.